To assess bone-density testing (BDT) use amongst prostate cancer survivors receiving androgen-deprivation therapy (ADT), and downstream implications for osteoporosis and fracture diagnoses, as well as pharmacological osteoporosis treatment in a national integrated delivery system.
Results
We found that a minority of patients received BDT (n = 2 502, 15%); however, the rate of testing increased to >20% by the end of the study period. Men receiving BDT were older at diagnosis and had higher-risk prostate cancer (both P < 0.001). Osteoporosis and fracture diagnoses, use of vitamin D AE calcium, and bisphosphonates were all more common in men who received BDT. After adjustment, BDT, and to a lesser degree ≥2 years of ADT, were both independently associated with incident osteoporosis, fracture, and osteoporosis treatment.
Introduction
Prostate cancer is a common malignancy in American men, many of whom eventually undergo androgen-deprivation therapy (ADT) as part of their prostate cancer management [1, 2] . Whilst ADT may be warranted to treat high-risk and advanced disease, it is associated with significant, often under-appreciated, adverse effects related to hypogonadism, including metabolic syndrome, cardiovascular disease, and decreased bone health [3] .
The effects of ADT on bone manifest as significantly decreased bone-mineral density (BMD), and consequently increased fracture risk [4] [5] [6] [7] [8] . Guidelines and existing literature recommend screening for osteoporosis at the time of ADT initiation to facilitate risk stratification and early pharmacological intervention where appropriate [9] [10] [11] [12] [13] . The National Comprehensive Cancer Network (NCCN) Task Force Report: Bone Health in Cancer Care states that 'in patients who will be undergoing therapy that lowers sex steroids, the NCCN Guidelines for Breast and Prostate Cancers recommend evaluation with baseline and periodic follow-up DXA scans to evaluate bone health and risk of fracture' [14] . However, existing data show that bone-density testing (BDT) rates remain below optimal levels [15] [16] [17] [18] [19] [20] . Bone-health assessment is especially warranted in patients with other risk factors for skeletal-related events, e.g. smoking, alcohol use, and low vitamin D levels [21] . These risk factors disproportionately afflict American veterans, who subsequently have higher rates of mortality after fractures, further magnifying the need for BDT [22] . Despite these increased risks, the national patterns of BDT use and subsequent osteoporosis management in this population have not been well categorised.
In this context, we characterised BDT use and outcomes in a national integrated delivery system cohort of veteran patients with prostate cancer treated with ADT. We evaluated BDT rates at the initiation of ADT, and assessed downstream skeletal-related outcomes including osteoporosis, fracture, and pharmacological treatment for osteoporosis. Better understanding of bone-health practice patterns and outcomes through this study will help to define the burden of bone disease amongst patients with high-risk prostate cancer and opportunities to improve the quality of their care.
Patients and Methods

Study Population
We used the Veterans Administration (VA) Central Cancer Registry to identify patients with an incident diagnosis of pathologically confirmed prostate cancer between 2005 and 2008 who were treated with ADT, defined as surgical orchidectomy or medical castration with an injectable GnRH agonist, using inpatient and outpatient pharmacy and utilisation coding [16] . More than 99% of the men in this cohort received medical castration, amongst whom 93% received goserelin, 4% leuprolide, and 3% another agent. We excluded patients with other cancer diagnoses, death within 30 days of diagnosis, or diagnosis at autopsy. We linked these data with VA administrative files containing inpatient, outpatient, laboratory, radiology, pharmacy, and facility data with follow-up through the year 2014. This allowed us to examine ADT use as well as BDT and other skeletal-related outcomes. We identified a cohort of 17 017 patients.
Outcomes
Our primary outcome was receipt of BDT at the patient level, consisting of either dual X-ray absorptiometry or quantitative CT. We assessed BDT by identifying claims submitted within 18 months before or after initiation of ADT, which should capture both recommended testing before ADT initiation as well as any delayed or follow-up monitoring. We utilised a larger time window than previous studies in order to maximise our capture of BDT performed surrounding ADT. As such our BDT rates may be biased to be slightly higher than those of other studies on this topic. Our secondary outcomes were downstream bone-health measures, including any administrative codes suggesting a new diagnosis of osteoporosis or any fracture after ADT initiation. We also queried pharmacy claims for any new prescriptions suggesting osteoporosis treatment after induction of ADT. Specifically, we assessed for dispensing of vitamin D AE calcium (calcium carbonate, calcium citrate, calcium acetate, calcium) as recommended for all patients initiating ADT, bisphosphonates (alendronate, pamidronate, risedronate, zoledronic acid, ibandronate), or denosumab, a bone-health treatment for metastatic prostate cancer that has also been shown to increase BMD and lower fracture rates in men receiving ADT [23] .
Statistical Analysis
We used descriptive statistics to assess differences in demographics, disease, and treatment characteristics between patients with prostate cancer treated with ADT who received BDT and those who did not. We examined covariates including age, race, ethnicity, marital status, employment status, Gleason score, D'Amico prostate cancer risk group, primary prostate cancer treatment, and Charlson Comorbidity Index (CCI) score (calculated using healthcare claims for the 12 months prior to prostate cancer diagnosis) [24, 25] . We used Student's t-tests and chi-squared testing as appropriate.
To assess the independent association of BDT use with our secondary outcomes of incident osteoporosis, fracture, and osteoporosis treatment, we fitted separate multiple logistic regression models for each outcome with the primary exposure of BDT. Given its particularly detrimental impact on bone health, we adjusted these models using an indicator variable for ≥2 years of ADT [4] [5] [6] [7] [8] , as well as the following covariates: age, race, ethnicity, marital status, D'Amico risk score, prostate cancer treatment type, and CCI score.
All analyses were conducted using Statistical Analysis System (SAS) software (SAS Institute, Cary, North Carolina, USA) and all testing was two-sided using an a of 0.05. This study was approved by the VA Ann Arbor Healthcare System Institutional Review Board.
Results
Amongst the 17 017 patients with prostate cancer receiving ADT, a minority received BDT during the study period (2 502, 15%). As shown in Table 1 , men receiving BDT were older and diagnosed with higher-risk disease (P < 0.001 for both). Amongst patients who received BDT there were slightly lower rates of initial treatment with a combination of radiation therapy and ADT (P < 0.001). Testing rates increased consistently over the years of the study period, as shown in Fig. 1 .
Bone-health outcomes amongst men with prostate cancer treated with ADT who did and did not receive BDT are shown in Table 2 . Recipients of BDT were significantly more likely to be diagnosed with osteoporosis and fracture, and more likely to receive treatment for osteoporosis (P < 0.001 for all). As shown in Fig. 2 , differences in bone-health outcomes amongst patients after the receipt of BDT were dramatic. For example, after BDT, diagnoses of osteoporosis and fracture increased nearly 10-and three-fold respectively. In addition, rates of vitamin D use more than doubled after BDT, while bisphosphonate use also increased~10-fold. Denosumab was rare but its use also increased.
As shown in Table 3 
Discussion
We found that roughly one in seven patients with prostate cancer receiving ADT underwent BDT within the 3 years surrounding initiation of castration in this national integrated delivery system. However, by the end of the study period in 2014 this number had increased to more than one in five. BDT was associated with dramatic increases in the diagnosis and treatment of osteoporosis, suggesting a non-trivial underlying burden of bone disease in untested men. Whilst good clinical judgment regarding which patients would benefit most from testing may lead to selection bias, it is unlikely that the nearly 90% of untested men in our cohort were at uniformly low-risk of osteoporosis and fracture. Even after controlling for patient and disease characteristics, both BDT and, to a lesser degree, an extended duration of ADT, were independent predictors of osteoporosis and fracture diagnoses. These findings confirm efforts are necessary to encourage bone-health testing and osteoporosis treatment in this high-risk population of prostate cancer survivors to decrease avoidable harms of castration with ADT.
Our present findings are consistent with prior data showing low rates of BDT in patients receiving ADT. Within veterans specifically, our present finding of a 15% BDT rate is congruent with previously published rates of~13% a decade ago, indicating a persistent quality gap [19, 20] . Although the uptrend in testing rates observed in the present study is encouraging, 20% of patients undergoing BDT is still well below an ideal testing rate. Whilst prior studies in veterans were limited to smaller geographical areas capturing several hundred patients, our national cohort is much larger, representing veterans across the USA, and reflects more contemporary practice patterns. Indeed, data from large studies in Medicare populations have also found persistently low rates varying from 6% to 14.5%, albeit with trends towards increasing utilisation over time, signalling systematic poor compliance with recommended care [16] [17] [18] . Recent results from other clinical contexts also underscore that the problem of low rates of BDT use among patients at high risk for bonerelated complications extends beyond the realm of prostate cancer into breast cancer [26] . The osteoporosis and fracture diagnoses identified in the present study underscore the importance of appropriate bonehealth testing amongst high-risk prostate cancer survivors. The striking five-fold difference in osteoporosis diagnosis between those who did and did not receive BDT suggests a significant amount of underlying disease in the 85% of men who were not tested. Moreover, the 10-fold increase in osteoporosis diagnosis after BDT, and two-to three-fold higher rates of osteoporosis treatment in the tested group compared to untested men demonstrates that testing yields actionable information for clinicians, who can intervene to potentially help avoid downstream bone complications especially in light of initiating ADT. Although the increases in fracture diagnoses were more modest, presumably discovered incidentally during evaluation for osteoporosis, this is a morbid complication highlighting that improvements in identification and treatment of skeletal fractures may be warranted.
In combination with the existing literature, our present findings support efforts to increase rates of appropriate BDT in men undergoing ADT, and suggest that such testing could in turn yield improved diagnosis and treatment of ADT's adverse effects on the skeletal system. However, exploring the behaviours and norms of physicians and patients that contribute to persistently poor compliance with guidelinerecommended bone-health assessment amongst men on ADT is critical and should help inform subsequent intervention design. At least four addressable reasons may be driving our present observations. First, providers may be unaware of the guideline recommendations to screen men receiving ADT for osteoporosis issued by groups such as the NCCN, although the negative impacts of ADT on bone health have long been established [14, 27] . Second, many clinicians may not feel comfortable using instruments such as the fracture risk assessment model (FRAX) tool, which combines BDT results with clinical risk factors to guide treatment (although it can be calculated without BMD) [28] . Third, there may be fragmentation amongst providers caring for these patients. Whilst specialists order and manage ADT, in the absence of metastatic disease it is often primary care clinicians who are tasked with the diagnosis and treatment of osteoporosis in men with prostate cancer. Last, the evidence supporting the impact of vitamin D, calcium, and bisphosphonates on decreasing clinically relevant fractures is mixed, generating confusion about the efficacy of these interventions and decreasing the likelihood of their utilisation [29, 30] . However, current recommended care includes placing men aged >50 years on vitamin D and calcium supplementation, a target not achieved in most of the present cohort [31] . It is possible some men in the present study may have obtained these supplements over the counter, but this is unlikely given VA pharmacy coverage and cost differences. Future work must better clarify the impacts of BDT and pharmacological intervention on subsequent fracture rates. Taken together, these findings suggest that further study is needed to address this gap in high-risk prostate cancer care and men's health in general.
There are several limitations to the present study. First, our results may not be generalisable to all patients with prostate cancer treated with ADT, as additional risks and unmeasured differences may be present amongst veterans. However, our present findings are consistent with results from other non-VA datasets, and the issues of low rates of BDT and low rates of subsequent treatment are not unique to this population. Further, our nationally representative cohort and the lack of age exclusions, as in Medicare studies, increases generalisability. Second, although our present study includes patients with follow-up through 2014, the 9-year span of our cohort from incident cancer diagnosis to last follow-up may suggest that our observed BDT rate could be an underestimate of current rates. However, the consistency of findings across studies and negligible increases indicate a persistent gap in care. Third, these retrospective data do not include the actual indications for BDT (other than initiating ADT) and therapeutic interventions, only whether or not they were received. Nonetheless, our use of incident diagnosis and pharmacy codes, coupled with our study design, support our conclusions of significantly underappreciated bone disease burden amongst these patients regardless of testing indication. It is possible that our present analysis may be an underestimate of the rates at which physicians are assessing osteoporotic fracture risk in these men, as we do not capture assessment methods that do not include BMD. However, given that BDT is the 'gold standard' method and is the approach recommended by the NCCN, we believe that these methods likely capture most of the bone-health assessments being performed in this population. It is also important to note that BDT is not causally associated with osteoporosis or fracture. Rather, the use of BDT allows for the identification of potentially subclinical bone disease, which can subsequently lead to earlier intervention and long-term reduction of harm. Lastly, our present analysis is subject to the inherent limitations of observational research and whilst we have attempted to control for confounding with multiple regression techniques, we were not able to fully account for unobserved confounders.
These limitations notwithstanding, our present results have important implications for men receiving ADT and those involved their care. First, urologists must be vigilant to minimise the burdens related to the adverse effects of ADT on bone health. Despite evidence recommending BDT in patients on ADT and trends towards increased use, rates of appropriate testing remain well below optimal levels. Second, from the standpoint of payers and policymakers, the costs of ADT-related adverse effects are significant, and interventions focused on mitigating the skeletal impacts of ADT have been 562 © 2017 The Authors BJU International © 2017 BJU International found to be cost-effective [32] . Increased attention should be directed towards encouraging the use of BDT in these patients. Last, the effects of ADT, osteoporosis, and fractures have significant negative implications for quality of life and survival. Increased use of appropriate BDT can potentially facilitate improved patient wellbeing and outcomes.
There appears to be significant under-diagnosis and treatment of osteoporosis amongst men with prostate cancer receiving ADT. Our present findings suggest substantial opportunities exist to reduce bone-related complications by improving use of BDT at ADT initiation to allow for early intervention. Better understanding of how providers care for these patients who are at high risk for bone-related complications, and how to most effectively target interventions to increase bone-health assessment is justified. In addition, quantifying the degree to which improved detection and treatment of osteoporosis can help in lower clinically relevant fracture rates in this high-risk population may help foster guideline concordant care. Efforts to optimise BDT amongst prostate cancer survivors initiating ADT may lead to increased quality of life and care.
